Lymphangitis medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
Line 272: | Line 272: | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Pasteurella}} | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Pasteurella Multocida}} | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | ||
Line 278: | Line 278: | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | '''''Adult''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | '''''Adult''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin-clavulanate]] 875 mg PO q12h | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin-clavulanate]] 875 mg PO q12h'''''<BR>OR<BR> ▸ '''''[[Ampicillin sulbactam]] 3 g IV q6h''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | '''''Children age >28 days''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | '''''Children age >28 days''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin-clavulanate]] 20 mg/kg PO divided q12h | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin-clavulanate]] 20 mg/kg PO divided q12h'''''<BR>OR<BR> ▸ '''''[[Ampicillin sulbactam]] 50 mg/kg IV q6h''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen''''' | ||
Line 288: | Line 288: | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | '''''Adult''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | '''''Adult''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ertapenem]] 1 g IM/IV q24h'''''<BR> OR <BR> ▸ '''''[[Cefoxitin]] 1 g IV q4h or 2 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Meropenem]] 1 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Imipenem cilastatin]] 500 mg IV q6h'''''<BR> OR <BR> ▸ '''''[[Doxycycline]] 100 mg PO/IV q12h'''''<BR> OR <BR> ▸ '''''[[TMP-SMX]] 1 double strength tablet (sulfamethoxazole 800 mg; trimethoprim 160 mg) PO q12h or 8-20 mg/kg IV divided q6-12h'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]] 400 mg PO/IV q24h | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ertapenem]] 1 g IM/IV q24h'''''<BR> OR <BR> ▸ '''''[[Cefoxitin]] 1 g IV q4h or 2 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Meropenem]] 1 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Imipenem cilastatin]] 500 mg IV q6h'''''<BR> OR <BR> ▸ '''''[[Doxycycline]] 100 mg PO/IV q12h PLUS [[Clindamycin]] 450 mg PO or 600 mg IV q8h'''''<BR> OR <BR> ▸ '''''[[TMP-SMX]] 1 double strength tablet (sulfamethoxazole 800 mg; trimethoprim 160 mg) PO q12h or 8-20 mg/kg IV divided q6-12h PLUS [[Clindamycin]] 450 mg PO or 600 mg IV q8h'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]] 400 mg PO/IV q24h PLUS [[Clindamycin]] 450 mg PO or 600 mg IV q8h''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | '''''Children age >28 days''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | '''''Children age >28 days''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''''[[Ertapenem]] 15 mg/kg IM/IV q12h'''''<BR> OR <BR> ▸ '''''[[Cefoxitin]] 160 mg/kg IV divided q4-6h'''''<BR> OR <BR> ▸ '''''[[Meropenem]] 20 mg/kg IV q8h'''''<BR> OR <BR> ▸ '''''[[Imipenem cilastatin]] 25 mg/kg IV q6h'''''<BR> OR <BR> ▸ '''''[[TMP-SMX]] 4-5 mg/kg (trimethoprim component) PO/IV q12h'''''<BR> PLUS <BR> ▸ '''''[[Clindamycin]] 10 mg/kg PO/IV q8h''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ertapenem]] 15 mg/kg IM/IV q12h'''''<BR> OR <BR> ▸ '''''[[Cefoxitin]] 160 mg/kg IV divided q4-6h'''''<BR> OR <BR> ▸ '''''[[Meropenem]] 20 mg/kg IV q8h'''''<BR> OR <BR> ▸ '''''[[Imipenem cilastatin]] 25 mg/kg IV q6h'''''<BR> OR <BR> ▸ '''''[[TMP-SMX]] 4-5 mg/kg (trimethoprim component) PO/IV q12h'''''<BR> PLUS <BR> ▸ '''''[[Clindamycin]] 10 mg/kg PO/IV q8h''''' | ||
|- | |- | ||
|} | |} | ||
Line 356: | Line 356: | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Clarithromycin]] 500 mg PO q12h | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Clarithromycin]] 500 mg PO q12h PLUS [[Ethambutol]] 15 mg/kg PO q24h'''''<BR> OR <BR> ▸ '''''[[Rifampin]] 600 mg PO q24h''''' | ||
|- | |- | ||
|} | |} | ||
Line 376: | Line 372: | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Terbinafine]] 500 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[Potassium iodide|Saturated solution of potassium iodide]] | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Terbinafine]] 500 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[Potassium iodide|Saturated solution of potassium iodide]] 5-50 drops q8h'''''<BR> OR <BR> ▸ '''''[[Fluconazole]] 400-800 mg/day PO''''' | ||
|- | |- | ||
|} | |} |
Revision as of 19:42, 3 June 2014
Lymphangitis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Lymphangitis medical therapy On the Web |
American Roentgen Ray Society Images of Lymphangitis medical therapy |
Risk calculators and risk factors for Lymphangitis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vendhan Ramanujam M.B.B.S [2]
Overview
Lymphangitis most often is an acute complication following an extension from the skin infection with the potential of a systemic spread. It has to be promptly treated with appropriate antibiotics along with analgesics, anti-inflammatory medications, warm and moist compresses. Certain conditions like nodular lymphagitis that is complicated by abscess and lymphedema with significant lymphatic obstruction may require surgical intervention.
Principles of Therapy
Therapy Based on Clinical Form
Acute Lymphangitis
Empiric Therapy
▸ Click on the following categories to expand treatment regimens.[1][2]
Mild - Moderate Acute Lymphangitis ▸ Adults ▸ Children age >28 days Severe Acute Lymphangitis ▸ Adults ▸ Children age >28 days |
|
Pathogen Based Therapy
▸ Click on the following categories to expand treatment regimens.[1][2]
Bacteria ▸ Streptococcus Pyogenes ▸ Methicillin Sensitive Staphylococcus Aureus ▸ Methicillin Resistant Staphylococcus Aureus ▸ Pasteurella Multocida |
|
Chronic Lymphangitis
Pathogen Based Therapy
▸ Click on the following categories to expand treatment regimens.[3][4][5]
Bacteria ▸ Mycobacterium Marinum Fungi ▸ Sporothrix Schenckii Parasites ▸ Brugia Malayi ▸ Wuchereria Bancrofti |
|
|
|
|
Other Therapies
- Analgesics and anti inflammatory medications can be used to control pain and inflammation.
- Hot, moist compresses can also be used to reduce pain and inflammation.
References
- ↑ 1.0 1.1 Moran GJ, Abrahamian FM, Lovecchio F, Talan DA (2013). "Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines". J Emerg Med. 44 (6): e397–412. doi:10.1016/j.jemermed.2012.11.050. PMID 23466022.
- ↑ 2.0 2.1 Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ; et al. (2011). "Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children". Clin Infect Dis. 52 (3): e18–55. doi:10.1093/cid/ciq146. PMID 21208910.
- ↑ Kauffman CA, Bustamante B, Chapman SW, Pappas PG, Infectious Diseases Society of America (2007). "Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America". Clin Infect Dis. 45 (10): 1255–65. doi:10.1086/522765. PMID 17968818.
- ↑ Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F; et al. (2007). "An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases". Am J Respir Crit Care Med. 175 (4): 367–416. doi:10.1164/rccm.200604-571ST. PMID 17277290.
- ↑ "Parasites - Lymphatic Filariasis".